

Patent Act

Crosbie (St. John's West)	Johnson (Bonavista—Trinity— Conception)	Ravis Redway Ricard Schellenberg (Nanaimo—Alberni)	Epp (Thunder Bay— Nipigon)	Kaplan Keeper Langdon MacLellan Manly McCurdy McDonald (Broadview— Greenwood)	Nystrom Ouellet Penner Riis Robinson Rompkey Rossi Young—35
Daubney	Joncas Kelleher Kempling Kindy King Ladouceur Lawrence Layton Lesick Lewis MacDonald (Kingston and the Islands)	Scott (Victoria—Haliburton)	Scott (Windsor West)	Murphy Nicholson (Trinity)	
Desjardins	Mailly Malone Mantha Martin Mayer Mazankowski McKinnon McKnight McMillan Minaker Mitges Moore Nicholson (Niagara Falls)	Scott (Hamilton—Wentworth)	Gronin Hopkins Hovdebo Isabelle		
Edwards	Nicholson (Niagara Falls)	Scowen Siddon Sparrow Speyer Stackhouse Stevens Stewart Taylor Towers Tremblay (Lotbinière)			
Ellis	Oberle O'Neil Paproski Pietz Plourde	Stewart Taylor Towers Tremblay (Lotbinière)			
Epp (Provencher)	Paproski Pietz Plourde	Tupper Turner (Ottawa—Carleton)			
Fennell	Paproski Pietz Plourde	Turner (Ottawa—Carleton)			
Ferland		Vankoughnet Vézina Vincent Warner White Wilson (Swift Current— Maple Creek)			
Fontaine		Winegard Wise Witer—104			
Forrestall					
Fraleigh					
Fretz					
Gass					
Gérin					
Gervais					
Girard					
Gottselig					
Graham					
Gray (Bonaventure—Îles-de- la-Madeleine)					
Greenaway					
Grisé					
Hamelin					
Hamilton					
Hardey					
Hawkes					
Hicks					
Hnatyshyn					
Holtmann					
Horner					
Hudon					
James					
Jardine					

NAYS

Members

Mr. Speaker: I declare the motion lost. The next question is on Motion No. 43. Mr. Orlikow moved:

Motion No. 43

That Bill C-22, be amended in Clause 15 by striking out lines 6 to 9 at page 25 and substituting the following therefor:

"(7) The Governor in Council shall make regulations defining, for the purposes of this section, the expression "research and development" which shall include the following criteria:

(a) all expenditures made under the requirements for a notice of compliance for phase one and phase two of clinical trials;

(b) all expenditures made for laboratory and preclinical work which lead to a notice of compliance;

but shall not include

(c) all expenditures made under the requirements for a notice of compliance for phase three of clinical trials; and

(d) all expenditures associated with the marketing of the medicine including all direct and indirect marketing schemes by patentees."

The House divided on the motion (Mr. Orlikow), which was negated on the following division:

(Division No. 123)

YEAS

Members

Althouse	Blackburn	de Corneille
Baker	(Brant)	de Jong
Benjamin	Broadbent	
Berger	Cassidy	

Mr. Speaker: I declare the motion lost. The next question is on Motion No. 44. Mr. Dingwall moved:

Motion No. 44

That Bill C-22, be amended in Clause 15 by striking out lines 10 to 13 at page 25 and substituting the following therefor:

"41.26(1) The Governor in Council may, at any time but no later than the expiration of four years after section 41.11 comes into force, by order, where he determines".

The House divided on the motion (Mr. Dingwall), which was negated on the following division: